Estrella Immunopharma Inc (ESLA) Stock Analysis

Verdict: AVOID

Early Phase I CAR-T trial progress is overshadowed by severe cash burn, negative net equity (-$10.37M), and active Nasdaq delisting warnings.

Investment score: 26/100

Analysis as of

Is Estrella Immunopharma Inc stock worth reviewing? The TradeMates thesis

The TradeMates model assigns an AVOID recommendation to Estrella Immunopharma Inc due to severe balance sheet deficits, immediate dilution risk, and Nasdaq compliance deficiencies, which outweigh early Phase I clinical trial developments.

7-factor investment score

Estrella Immunopharma Inc opportunities and risks

What speaks for ESLA

What speaks against ESLA

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ESLAn/a0.0xn/a0.0%0.0%-21.9%
HOWLn/a2.3xn/a86.4%-164.8%-63.3%
IBIOn/a461.6x0.3x100.0%-33044.0%-51.6%
BMEAn/a0.0xn/a0.0%0.0%-108.5%
ANVSn/a0.0xn/a0.0%0.0%-101.6%
TVGNn/a0.0xn/a0.0%0.0%-42.8%
Peer mediann/a0.0xn/a0.0%0.0%-63.3%

Frequently asked questions about Estrella Immunopharma Inc (ESLA)

Is ESLA stock a good investment?

The TradeMates model rates Estrella Immunopharma Inc as AVOID with an investment score of 26/100. The TradeMates model assigns an AVOID recommendation to Estrella Immunopharma Inc due to severe balance sheet deficits, immediate dilution risk, and Nasdaq compliance deficiencies, which outweigh early Phase I clinical trial developments. This is algorithmic model output, not personal investment advice.

Is ESLA stock a buy?

The TradeMates model verdict for ESLA is AVOID with an investment score of 26/100. Treat this as a model signal to review, not a personal buy recommendation.